The ketone body \(\beta\)-hydroxybutyric acid influences agouti-related peptide expression via AMP-activated protein kinase in hypothalamic GT1-7 cells

Thomas Laeger\(^1\), Ralf Pöhland\(^2\), Cornelia C Metges\(^1\) and Björn Kuhla\(^1\)

\(^1\)Research Unit Nutritional Physiology “Oskar Kellner” and \(^2\)Research Unit Reproductive Biology, Leibniz Institute for Farm Animal Biology (FBN), Wilhelm-Stahl-Allee 2, 18196 Dummerstorf, Germany

(Correspondence should be addressed to B Kuhla; Email: b.kuhla@fbn-dummerstorf.de)

Abstract

\(\beta\)-Hydroxybutyric acid (BHBA) acts in the brain to influence feeding behaviour, but the underlying molecular mechanisms are unclear. GT1-7 hypothalamic cells expressing orexigenic agouti-related peptide (AGRP) were used to study the AMP-activated protein kinase (AMPK) pathway known to integrate dietary and hormonal signals for food intake regulation. In a 25 mM glucose culture medium, BHBA increased intracellular calcium concentrations and the expression of monocarboxylate transporter 1 (MCT1 (SLC16A1)). Phosphorylation of AMPK-\(\alpha\) (PRKAA1 and PRKAA2) at Thr172 was diminished after 2 h but increased after 4 h. Its downstream target, the mammalian target of rapamycin, was increasingly phosphorylated on Ser2448 after 2 h but not changed after 4 h of BHBA treatment. After 4 h, BHBA treatment also increased \(Agrp\) mRNA expression. This increase was prevented by preincubation with the AMPK inhibitor Compound C. The inhibition of MCT1 activity by \(p\)-hydroxymercuribenzoate suppressed BHBA-stimulated AMPK phosphorylation but did not prevent BHBA-induced \(Agrp\) mRNA expression. This finding demonstrates that BHBA triggers the AMPK pathway resulting in orexigenic signalling under 25 mM glucose culture conditions. Under conditions of 5.5 mM glucose, however, BHBA marginally increased intracellular calcium but significantly decreased AMPK phosphorylation and \(Agrp\) mRNA expression, demonstrating that under physiological conditions BHBA reduces central orexigenic signalling.


Introduction

As an important intermediate of amino and fatty acid catabolism, \(\pi\)-\(\beta\)-hydroxybutyric acid (BHBA), like glucose, can be used by the brain to provide energy particularly for suckling newborns (Hawkins et al. 1971). BHBA may access the brain by crossing the blood–brain barrier as well as entering hypothalamic neurons via the monocarboxylate transporter 1 (MCT1 (SLC16A1); Tildon & Roeder 1988, Ainscow et al. 2002, Morris & Felmlee 2008).

The impact of BHBA on satiety has recently been summarised (Laeger et al. 2010). In contrast to diabetic hyperketonaemia, which is usually associated with hyperphagia (Goodman 1987, Friedman & Ramirez 1994, Toyonaga et al. 2002), i.e.v. application of BHBA rather diminishes food intake (Sakata et al. 1982, Arase et al. 1988). Based on these findings, it has recently been suggested that BHBA may also be involved in the regulation of hypophagic responses (Laeger et al. 2010); however, the underlying molecular mechanisms are still not resolved.

In the hypothalamus, one of the central regulators of food intake and energy homeostasis, the AMP-activated protein kinase (AMPK (PRKAA2)) pathway is activated in response to an increase in the AMP:ATP ratio and integrates extracellular hormonal and nutrient signals (Hardie et al. 1999, Minokoshi et al. 2004, Xue & Kahn 2006, Kola 2008). Activation of AMPK (phosphorylation of Thr172 at the \(\alpha\) subunit) leads to an increased expression of orexigenic neuropeptides (NP) such as NPY and agouti-related peptide (AGRP) and a decreased expression of anorexigenic NP such as pro-opiomelanocortin (POMC; Kola 2008). The inhibition of AMPK by Compound C (Cpd C) prevents these expression changes (Iwasaki et al. 2007, Shimizu et al. 2008).

Incubation of hippocampal neurons with BHBA but without glucose maintains the cellular ATP level (Arakawa et al. 1991), suggesting that BHBA may modulate hypothalamic AMPK activity. Upstream kinases of AMPK are the tumour suppressor LKB1 (STK11) kinase and the \(Ca^{2+}\)/calmodulin–dependent protein kinase I (CAMK1 (CAMK1)), the latter dependent on intracellular \(Ca^{2+}\) release (Hawley et al. 2003, Hurley et al. 2005, Witters et al. 2006). Once phosphorylated at Thr172, AMPK may inhibit its downstream target mammalian target of rapamycin (mTOR), which in turn integrates amino acid and insulin signalling and thereby...

The aim of this study was to investigate the effect of BHBA on hypothalamic orexigenic signalling. GT1-7 cells have been successively used to investigate orexigenic signalling (Yang et al. 2005, Li et al. 2006, Morrison et al. 2007, Hayes et al. 2011). Using this model, we could show that BHBA increases intracellular Ca²⁺ release and modulates the phosphorylation of AMPK and mTOR in a time- and glucose-dependent manner. Changes in AMPK phosphorylation were at least in part mediated by MCT1 and accompanied with an altered Agrp mRNA expression.

Materials and Methods

Cell culture of hypothalamic GT1-7 cells

Murine-immortalised GT1-7 hypothalamic cells were kindly provided by Dr Franz Schäfer, University of Heidelberg, Germany. GT1-7 cells were developed by Mellon et al. (1990) from a tumour obtained from a transgenic mouse in which the gonadotropin-releasing hormone (GNRH (GNRH1)) promoter sequence drives the expression of SV40 T antigen (Tg(Lhb-TAg)#Plm) but does not alter the expression of Agrp. GT1-7 cells were seeded on 6 cm culture plates and maintained in DMEM (with 4.5 g/l (25 mM) or 1 g/l (5.5 mM) glucose, L-glutamine, sodium pyruvate and 3.7 g /l NaHCO₃) supplemented with 10% (v/v) FCS and 1% (v/v) penicillin–streptomycin solution (PAN Biotech GmbH, Aidenbach, Germany) at 37°C in 5% CO₂ atmosphere. The culture medium was changed twice a week and cultures were passaged at 80% confluence after trypsinisation (0.05%, w/v). Changes in cell morphology and growing conditions were carefully monitored using an inverted microscope. To reduce mitogenic effects, GT1-7 cells were preincubated in 0·1% (v/v) FCS/DMEM for 24 h. BHBA was added to the culture medium either alone or 5 min after preincubation with the MCT1 inhibitor p-hydroxymercuribenzoate (pHMB; Sigma–Aldrich; dissolved to 0.5 mM stock solution using H₂O or DMSO as described earlier. The dilution of the to 10 mM in dimethyly sulfoxide (DMSO)) in concentrations were passaged at 80% confluence after trypsinisation (0·05%, w/v). Changes in AMPK phosphorylation were at least in part mediated by MCT1 and accompanied with an altered Agrp mRNA expression.

Methods and Techniques

Western immunoblot analysis

The cell culture medium was withdrawn and GT1-7 cells were solubilised in 80 μl lysis buffer containing 50 mM Tris (pH 7.8), 1 mM EDTA (Pharmacia Biotech), 10 mM NaF (Fisher Scientific, Schwerte, Germany), 1% (v/v) Igepal CA-630 (Sigma–Aldrich), 0·1% (v/v) Triton X-100 (Pharmacia Biotech), 0·5% (v/v) deoxycholic acid (DOC; Sigma), 0·1% (w/v) sodium dodecyl sulfate (SDS; USB Corporation, Cleveland, OH, USA) and Roche Phospho-Stop tablets (one tablet/10 ml buffer; Roche) on ice. After centrifugation (4 °C, 10 min, 15 700 g), the supernatant was collected and the protein content was quantified using CBQCA Protein Quantitation Kit C-6667 (Molecular Probes, Inc., Eugene, OR, USA) according to the manufacturer’s protocol. For SDS gel electrophoresis, 25 μg sample solutions were diluted to the same amount with SDS sample buffer containing 62·5 mM Tris (pH 6·8), 2%(w/v) SDS, 10% (v/v) glycerol, 5%(v/v) 2-mercaptoethanol and 0·001%(v/v) bromophenol blue. The samples were boiled for 5 min and electrophoresed through a 12% (w/v) SDS polyacrylamide gel. Proteins were then transferred to nitrocellulose membranes. Membranes were blocked with 3% (w/v) BSA in TBST buffer (20 mM Tris/HCl, 0·9%(w/v) NaCl, 0·05%(v/v) Tris (TWEEN-20; pH 7·6) and incubated with the primary rabbit antibodies against AMPK-α, phospho-AMPK-α Thr172, mTOR, phospho-mTOR Ser2448 (each from Cell Signaling Technology, Inc., Danvers, MA, USA), chicken-anti-MCT1 (Millipore Corporation, Billerica, MA, USA) or after stripping and re-probing with mouse-anti-β-tubulin antibody (Covance, Inc., Emeryville, CA, USA) at 4 °C for 12 h (each 1:1000 dilution). Membranes were then washed with TBST, incubated with the corresponding HRP-conjugated anti-mouse, anti-rabbit or anti-chicken IgG (each 1:3000, 60 min at room temperature). After washing three times with TBST, the membranes were transferred to ECL solution (Pierce ECL Western Blotting Substrate; Thermo Scientific, Rockford, IL, USA) for 1 min and exposed to Clear Blue X-Ray Film (CL-XPosure Film; Thermo Scientific) for 0·5–2 min. Bands were scanned and quantified using ImageJ 1·42q (Wayne Rasband, National Institutes of Health, Bethesda, MD, USA). The level of phosphorylation of an assayed enzyme was calculated relative to the total amount of this enzyme. MCT1 levels were assessed relative to β-tubulin levels.

RNA extraction, reverse transcriptase and quantitative real-time PCR analysis

Total RNA of GT1-7 cells was extracted using a Nucleospin RNA XS kit (Macherey-Nagel GmbH, Düren, Germany), subsequently quantified by measuring the absorbance at 260 and 280 nm (NanoPhotometer; Implen, Munich, Germany) and stored at −80 °C until analysis. The quality of extracted RNA was judged by northern analysis and inspection of the 28S and 18SrRNA bands. The extracted RNA (0·5 μg) was subjected to a RT-PCR using Transcriptor High Fidelity cDNA Synthesis Kit (Roche) with anchored oligo(dT)₁₈ primer (2·5 μM) at 65 °C for 10 min to ensure denaturation of RNA secondary structures. Subsequently, Protector RNase Inhibitor (20 U, 1 mM), deoxynucleotide mix (1 mM), dithiothreitol (5 mM) and Transcriptor High Fidelity Reverse Transcriptase (10 U) were added and RT was performed using MgCl₂ (8 mM) for 30 min at 50 °C. The transcriptase was subsequently inactivated by heating at 85 °C for 5 min.


www.endocrinology-journals.org
The expression level for Agrp was determined relative to
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) using
the following primers: Agrp, sense 5'-TGA CTG CAA TGT
TGC TGA GTG GTG-3' and anti-sense 5'-TAG GTG CGA
CTA CAG AGG TTC GTG-3' (391 bp fragment); Gapdh,
sense 5’-AAC TTT GGC ATT GTG GAA GG-3' and anti-
sense 5’-ACA CAT TGG GGG TAG GAA CA-3' (223 bp).
Primer searches were carried out against previously identified
genes using the Basic Local Alignment Search Tool (BLAST)
program (http://www.ncbi.nlm.nih.gov/BLAST/) of
the GenBank database (National Center for Biotechnology
Information, Washington, DC, USA).

For quantification of Agrp and Gapdh transcript levels, real-
time PCR was performed using LightCycler FastStart DNA
MasterPlus SYBR Green I (Roche) under each optimised
condition of annealing at 59 °C, according to the manufactur-
er’s protocol. An aliquot of the PCR product was
electrophoresed on a 3% (w/v) agarose gel and visualised by
ethidium bromide staining to confirm purity and size. To
analyse the relative changes in gene expression, the 2^ΔΔCT
method was used (Livak & Schmittgen 2001).

Ca²⁺ imaging and confocal laser scanning microscopy
Hypothalamic GT1-7 cells were washed with PBS
(50 mM Na₂HPO₄, 0.85% (w/v) NaCl, 0.25 (w/v) KCl;
PH 7.4), incubated with the cell-permeant acetoxymethyl
ester Fluo-4 at 3 μM and 0.07% (v/v) Pluronic F-127
(Molecular Probes) in 0.1% (v/v) FCS/DMEM for 45 min at
37 °C in 5% CO₂ atmosphere. After loading the GT1-7 cells
were washed with PBS and incubated in indicator-free 0.1%
(v/v) FCS/DMEM for further 30 min. Afterwards, GT1-7
cells were incubated in a Microscope Incubator (XL-3-LSM;
Pecon, Erbach, Germany) at 37 °C in 5% CO₂ atmosphere
and analysed for fluorescence at a confocal laser scanning
microscope (LSM 5 Pascal, Axiocor 200M, Zeiss, Jena,
Germany) and Zen 2007 Software (Carl Zeiss) before and
after BHBA stimulation in concentrations as indicated. For
the measurement of green fluorescence, 488 nm line of
Argon laser (30 mW) and a 505–530 nm narrowband filter
were used. Stacks of images (ten images per second, 256×256
pixel) were recorded using a 20× lens and the provided
software. Analysis 3.2 (SIS, Münster, Germany) was used to
create regions of interest (ROIs) exactly enclosing the GT1-7
cells and to measure the mean intensity in ROIs according to
Pöhland et al. (2008).

Statistical analysis
Data were statistically analysed by Systat version 10 using the
F-test (see figure legends) and a two-way (BHBA concentra-
tion and incubation time) ANOVA (main effects: BHBA
treatment and incubation time) followed by comparison of
means using the Tukey’s test. A statistically significant
difference was considered when P≤0.05.

Results
Effect of BHBA on AMPK and mTOR signalling in
hypothalamic GT1-7 cells
Based on the previous studies showing that neurons incubated
for 2 h with BHBA revealed increased ATP levels (Arakawa
et al. 1991), we first cultured hypothalamic GT1-7 cells in
25 mM glucose-containing medium as described earlier
(Li et al. 2006, Coyral-Castel et al. 2008, Hayes et al. 2011)
and investigated whether BHBA modulates AMPK phos-
phorylation. Incubation with 1.5, 3 and 6 mM BHBA for
2 and 4 h revealed that treatment with 6 mM BHBA resulted
in a 21% decrease of AMPK-ζ phosphorylation after 2 h,
whereas after 4 h AMPK phosphorylation significantly
increased by 132% when compared with t=0 (Fig. 1A; for
each time n=4–8). After 1, 6 and 8 h, AMPK-ζ phosphorylation
was not changed when compared with t= 0 (data not shown). In addition, GT1-7 cells treated with only
1.5 and 3 mM BHBA revealed a significant decrease in
AMPK phosphorylation after 2 h, but after 4 h AMPK phosphorylation did not differ in comparison with t=0
(Fig. 1A). In addition, the loading control with β-tubulin
revealed no differences between time points.

As BHBA is primarily used by the brain when glucose is
reduced (Lindsay & Setchell 1976, Arakawa et al. 1991), we
next studied the effect of BHBA on AMPK-ζ phosphory-
lation in a lower (5:5 mM) glucose-containing medium,
which is more physiological (see also section on BHBA and
glucose concentrations). In contrast to the results described in
Fig. 1A, incubation with 1.5 and 3 mM BHBA for 2 and 4 h,
respectively, revealed that treatment with 3 mM BHBA
resulted in a 42% decrease of AMPK-ζ phosphorylation
after 4 h, whereas 1.5 mM BHBA had no effect on AMPK-ζ
phosphorylation (Fig. 1B; for each time n=5–11). The use of
6 mM BHBA, however, resulted in a 35% decrease of
AMPK-ζ phosphorylation after 4 h. These results demon-
strate that 6 mM BHBA induced a significant (P<0.05)
alteration of AMPK-ζ phosphorylation after 2 and 4 h.
Hence, we used 6 mM BHBA in the following experiments.

In 25 mM glucose-containing medium, phosphorylation
(inhibition) of the downstream target of AMPK, mTOR, at
Ser2448 significantly increased to 129% after 2 h when incu-
bation with 6 mM BHBA (Fig. 2A; for each time n=6–8).
After 4 h, mTOR phosphorylation did not differ compared
with t=0 (P=0.1). In contrast, in 5-5 mM glucose-
containing medium, phosphorylation of mTOR did not
change upon BHBA stimulus (Fig. 2C; for each time n=5).

Role of MCT1 for BHBA-induced AMPK phosphorylation
The uptake of BHBA into cells might be mediated by the
MCT1 system and its presence has recently been confirmed in
hypothalamic neurons (Ainscow et al. 2002, Morris & Felmlee
2008). Thus, we examined whether BHBA influences the
expression of MCT1. We found that in 25 mM glucose-

www.endocrinology-journals.org
The effect of BHBA on AMPK phosphorylation was abolished when cells were preincubated with the specific AMPK inhibitor Cpd C (10 μM; Fig. 3A).

In low-glucose medium (5–5 mM), diminished AMPK-α phosphorylation elicited by BHBA was prevented by either blockade of MCT1 or AMPK respectively (Fig. 3B; for each time n = 5). These results suggest that intracellular BHBA uptake mediated by MCT1 may trigger AMPK signalling.

**BHBA increases Ca²⁺ efflux in GT1-7 cells**

As the Ca²⁺/CAMK and the Ca²⁺/CAMK kinase (CAMKK (CAMKK2)) act as upstream signals for the phosphorylation of AMPK-α at Thr172 (Hawley et al. 2005, Hurley et al. 2005), we evaluated the effect of BHBA on intracellular [Ca²⁺]. Our results reveal that treatment with 6 mM BHBA in 25 mM glucose led to a rapid [Ca²⁺] increase, as demonstrated by the increased intracellular Fluo-4 fluorescence (Fig. 4A and C). The onset of [Ca²⁺], induced with 2 mM BHBA occurred at a later time, to a lower extent, and was sustained for a shorter period of time compared with the 6 mM BHBA stimulus (Fig. 4A; n = 5). Under conditions of 5–5 mM glucose, however, we only found a marginal [Ca²⁺] increase after treatment with 6 mM but not with 2 mM BHBA (Fig. 4B; n = 4).

**Regulation of Agrp mRNA expression by BHBA under different glucose concentration**

AMPK is known to control food intake by regulating the expression of orexigenic and anorexigenic NP in the hypothalamus (Minokoshi et al. 2004, Shimizu et al. 2008). Therefore, we next investigated the impact of BHBA on orexigenic Agrp expression. In 25 mM glucose, we found that transcripts of orexigenic Agrp relative to Gapdh were significantly increased after 4 and 7 h incubation with 6 mM BHBA (Fig. 5A; for each time n = 5–12). As AMPK phosphorylation and Agrp expression were highest after 4 h, subsequent blocking experiments were performed for this time only. Blockade of AMPK by Cpd C (10 μM) significantly decreased BHBA-induced Agrp expression (Fig. 5A), indicating that BHBA elicits orexigenic signalling specifically via AMPK. Furthermore, treatment with the MCT1 inhibitor pHMB (1 μM) did not affect BHBA-mediated Agrp expression (Fig. 5A), suggesting that BHBA may either enter the cells by bypassing MCT1 or it binds to a BHBA membrane receptor without entering the cells. Regardless, our results demonstrate that BHBA activates the AMPK→AGRP pathway under conditions of 25 mM glucose.

By contrast, cells incubated in 5–5 mM glucose responded with decreased (42–46%) Agrp mRNA expression after 4 and 7 h of BHBA treatment (Fig. 5B; for each time n = 7–13), indicating that the ratio between BHBA and glucose determines feed intake-related signalling. This reduction could be prevented by pre-incubation with Cpd C, indicating that BHBA diminishes orexigenic signalling via AMPK under

---

**Figure 1** Effect of BHBA on AMPK in hypothalamic GT1-7 cells. GT1-7 cells maintained in (A) 25 mM or (B) 5–5 mM glucose-containing medium were stimulated with or without BHBA in concentrations as indicated for 2 and 4 h. Cell lysates were examined by western blot analysis with AMPK-α and phospho-specific AMPK-α Thr172 antibodies. The densitometric ratio of pAMPK/AMPK was calculated against the ratio of untreated controls and is presented as mean ± s.o. for each time point. A representative blot is shown below the graphs.

---


www.endocrinology-journals.org
BHBA and glucose concentrations

Under normoglycaemic conditions, ketone bodies may occur in substantial concentrations (~0.5 mM) in humans (Laffel 1999). In ruminants, BHBA plasma concentration is even higher during and after food intake due to oxidation of ruminal butyrate in ruminal epithelial cells (van Soest 1994, Duske et al. 2009). During times of high energy demands, such as pregnancy, lactation, exercise and fasting, glucose becomes less available and energy stores are mobilised from body fat, and ketone bodies become an important respiratory fuel (Hawkins & Biebuyck 1979). Thus, fasting may increase blood BHBA levels by 5–8 mM (Lindsay & Setchell 1976, Cahill & Veech 2003). In adult humans with diabetic ketoacidosis, circulating BHBA may even reach 3–14 mM while glucose is about 26 mM (Friedman & Ramirez 1994, Sheikh-Ali et al. 2008). In humans as well as in ruminants, circulating BHBA is also elevated in response to chronic consumption of a ketogenic diet (Brehm et al. 2003, Boden et al. 2005, Duske et al. 2009). Because of the relatively high fat and low carbohydrate content in rodent milk (mouse: 17–30% fat, 1–2% carbohydrates), BHBA is touted as one of the most important energy sources of suckling rodents (Hawkins et al. 1971, Görs et al. 2009). Thus, it is seems that among species (gastric, hind-gut or reticulorum fermenters) and their developmental stages, a different hypothalamic sensitivity to BHBA exists. The similarity between all species, however, is that the mammalian brain can use BHBA instead of glucose primarily under hypoglycaemic conditions and that the extent of usage depends on the physiological state (Owen et al. 1967, Lindsay & Setchell 1976, Laeger et al. 2010).

The extracellular glucose concentration in the brain is about 25% of the circulating glucose and varies between different brain areas and physiological states (Silver & Erecinska 1994, de Vries et al. 2003). Under hyperglycaemic conditions, the extracellular glucose level in the brain may reach >10.5 mM (Silver & Erecinska 1994), while it is about 1.4 mM in fed rats and 0.7 mM in overnight-fasted rats (de Vries et al. 2003). Thus, the 25 mM glucose concentration used in our in vitro study seems to correspond to about 100 mM plasma glucose, which appears to be pathophysiological. This raises the question about the physiological relevance of our cell culture approach. However, because of the different metabolic rate and the diffusion-controlled availability of nutrients, for example, the glucose concentration determined in vitro could

Figure 2 Effect of BHBA on mTOR and MCT1 in hypothalamic GT1-7 cells. GT1-7 cells cultured in 25 mM (A and B) or 5.5 mM (C and D) glucose were stimulated with or without BHBA (6 mM). Cell lysates were probed with (A and C) antibodies against Ser2448 mTOR and total mTOR or with (B and D) antibodies against MCT1 and β-tubulin. The densitometric ratio of pmTOR/mTOR and MCT1/β-tubulin, respectively, was calculated. The ratio between BHBA-treated and -untreated controls is presented as mean ± S.D. (for each time n24 = 6–8 and n25 = 5). Mean values with different lowercase letters differ with P < 0.05 (Tukey’s test; ANOVA: P < 0.05, FA = 3.4, FB = 6.5, FC = 0.4, FD = 0.5). A representative blot is shown below the graphs.
also used glucose concentrations between 5.5 and 25 mM for
et al.
Coyral-Castel
AMPK-
were examined by western blot analysis with phospho-specific
the incubation with or without 6 mM BHBA for 4 h. Cell lysates
m
10
were examined by western blot analysis with phospho-specific
AMPK-α Th172/AMPK-α. The densitometric ratio of pAMPK/AMPK was determined. Data are calculated as fold change of untreated controls and are presented as
mean ± s.d. (for each time n25 = 5-6 and n5.5 = 5). Mean values with
different lowercase letters differ with P<0.05 (Tukey’s test; ANOVA:
P<0.05, Fα=4-5, Fβ=3-2). A representative blot is shown below the graphs.

not be simply applied to the cell culture. GT1-7 cells were generated via tumourigenesis (Mellon et al. 1990) and possess a
approximately ten times higher glucose uptake and glycolysis rate compared with non-oncogenic cells (Dang & Semenza 1999). Considering this fact, 25 and 5-5 mM glucose used in
cell culture would correspond to 2.5 and 0.55 mM of
extracellular glucose available for non-oncogenic cells, which in turn reflects the glucose concentration as measured
in the brain (Silver & Erecinska 1994). Moreover, a number of
recent investigations (Lee et al. 2005, Li et al. 2006,
also used glucose concentrations between 5.5 and 25 mM for
GT1-7 cells, making our results comparable with these
studies, while the use of <5.5 mM glucose led to cell death (Honegger et al. 2002).

One might assume that differences also exist between
circulating and extracellular BHBA concentrations in the
brain, but currently there are no data about it. However,
further studies in whole animals are required to determine
extracellular BHBA brain concentrations under various
physiological conditions. Those data would help to examine,
in a physiologically relevant range, which concentrations in
the brain are to be adjusted in in vivo experiments to provoke
alterations in feed intake signalling and in feed intake. When,
however, the glucose/BHBA ratio (see below) instead of
the absolute metabolite concentration is considered, our
cell culture model mimics the in vivo situation and allows
the investigation on principle signalling pathways induced
by BHBA.

BHBA uptake via MCT1

Investigations on dissociated brain cells of rats revealed two
forms of neuronal BHBA uptake: diffusion and carrier-
mediated transport systems (Tildon & Roeder 1988). Members of the H+-coupled MCT (SLC16A1) family
(MCT1, MCT2 (SLC16A7) and MCT4; Morris & Felmlee 2008)
and members of the solute carrier (SLC) group, the
sodium-coupled MCT1 (SMCT1; SLC5A8), have been
identified as neuron-specific transporters for BHBA (Martin
et al. 2006). MCT1 is abundantly distributed throughout the
brain with high levels in the hypothalamic region and adjusted
to the local glucose transporter GLUT1 (SLC2A1; Maurer
et al. 2004). In our study, we demonstrated significantly
increased MCT1 expression by 4 h of BHBA incubation in
25 mM glucose-containing medium. However, to date,
detailed mechanisms of transcriptional regulation of MCT1
expression by BHBA are not known. In addition, inhibition
of MCT1 via 1 µM pHMB suppresses (but not fully prevents)
BHBA-induced AMPK phosphorylation in 25 mM glucose
and AMPK dephosphorylation in 5.5 mM glucose respect-
ively. Higher concentrations of pHMB (1 mM), however,
did not lead to a further MCT1 blocking effect but rather to cell
death (data not provided). Furthermore, we have shown that
in 25 mM glucose-containing medium, pHMB stimulates
AMPK phosphorylation in the absence of BHBA, because the
entrance of other metabolites (fuels) transported by MCT1,
such as lactate, pyruvate, acetate and acetoacetate, is also
blocked, which would thus lead to an increase in AMPK
phosphorylation. Moreover, although pHMB suppresses
AMPK phosphorylation in the presence of BHBA, it did not
prevent increases in Agrp expression in 25 mM glucose. These
results suggest that BHBA triggers Agrp expression not
exclusively via MCT1. For example, BHBA could affect
intracellular signalling without entering the cell by binding to
the membrane G protein-coupled receptor 109A (GPR109A
(NiACR1)), which has been shown to be expressed in several
portions of the brain in multiple species (Tiggesmeyer et al. 2011).
BHBA treatment occurred between the control and the 6 mM BHBA group. MCT1 expression under low-glucose conditions serves as a metabolite for ATP production and thus contributes to decreased AMPK phosphorylation.

Studies performed in 5.5 mM glucose-containing medium, however, reveal that BHBA-induced AMPK–α phosphorylation is contrarily regulated compared with culture conditions in 25 mM glucose. This might be due to lowered activity of Ca\(^{2+}\)-dependent kinases (see below) located upstream of AMPK or due to the fact that BHBA under low-glucose conditions serves as a metabolite for ATP production and thus contributes to decreased AMPK phosphorylation.

Based on the fact that the loading control β-tubulin did not change between times, changes in the phosphorylation of AMPK–α is not the result of changes in total AMPK–α. This is strengthened by another study with GT1-7 cells, which demonstrated that high glucose supplementation (25 mM) suppresses AMPK–α phosphorylation without changes in the total AMPK–α levels (Lee et al. 2005).

**Effect of BHBA on mTOR signalling**

One of the downstream targets of AMPK, mTOR, is a highly conserved serine/threonine kinase, integrating nutrient and hormonal signals to control growth and development (Bolster et al. 2002, Kimura et al. 2003). In the arcuate nucleus of the hypothalamus, mTOR is localised in POMC and AGRP/NPY neurons that are involved in food intake regulation (Cota et al. 2006). Fasting induces a decrease in mTOR phosphorylation at Ser\(^{2448}\) (Cota et al. 2006). Our results demonstrate that BHBA increases phosphorylation of mTOR at Ser\(^{2448}\) after 2 h, which inversely corresponds to a decline of p-AMPK. Conversely, reduced mTOR phosphorylation

The latter assumption is supported by the finding that under conditions of 5.5 mM glucose, BHBA indeed reduced AMPK phosphorylation but did not alter MCT1 expression. Thus, under low-glucose conditions, cells seem to dispense for the regulation of MCT1 expression, enabling BHBA to enter the cells particularly via a non-MCT1 mediated pathway. In this case, supraphysiological BHBA is not required for an increase in MCT1 expression.

**Figure 4** BHBA increases [Ca\(^{2+}\)]\(_i\) in GT1-7 cells cultured in (A) 25 and (B) 5.5 mM glucose-containing DMEM. After stimulation with BHBA (2 and 6 mM), changes of the intracellular Fluo-4 fluorescence were recorded by confocal laser-scanning microscopy (C, e.g. in 25 mM glucose). Control incubations were performed with water (D). The fluorescence intensity after application of BHBA or water (indicated by an arrow), respectively, was recorded in five (25 mM glucose) and four (5.5 mM glucose) independent experiments each with seven to ten cells. Data are presented as mean ± s.d. Significant differences (P<0.05; ANOVA) in 25 mM glucose between the control and the 6 mM BHBA group occur >50 s after application and between the control and the 2 mM BHBA group >64 and <96 s. Significant differences in 5.5 mM glucose between the control and the 6 mM but not the 2 mM BHBA treatment occurred >50 and <100 s after application.
Effect of BHBA on \( [Ca^{2+}]_i \)

Besides the activation of AMPK by LKB1–AMP, \( Ca^{2+} \)/CAMKK may activate its downstream target CAMKI that in turn also phosphorylates AMPK-\( \alpha \) at Thr\(^{172} \) (Witters et al. 2006). Therefore, we investigated the effect of BHBA on intracellular \( [Ca^{2+}]_i \). Our results show that BHBA elicits a faster increase of \( [Ca^{2+}]_i \), compared with AMPK phosphorylation, suggesting that BHBA triggers the AMPK pathway via \( Ca^{2+} \)-dependent signalling under conditions of 25 mM glucose. In the presence of 5:5 mM glucose, BHBA induces a only marginal \( [Ca^{2+}]_i \), influx, indicating that \( Ca^{2+} \)-dependent kinases should not significantly phosphorylate AMPK under these conditions. On the other hand, a previous study revealed that \( [Ca^{2+}]_i \), raised via AMPK activation in hypothalamic neurons (Kohno et al. 2008). However, further studies, e.g. using calcium-binding agents, are required to determine the association between \( [Ca^{2+}]_i \), increase and AMPK signalling triggered by BHBA.

Effect of BHBA on \( Agrp \) mRNA expression

Hypothalamic AMPK inhibition reduces \( Agrp \) expression (Shimizu et al. 2008) and induces a reduction of food intake (Minokoshi et al. 2004, Xue & Kahn 2006). In contrast, increased activation of AMPK in the arcuate nucleus of the hypothalamus leads to an increased expression of \( Agrp \) (Shimizu et al. 2008). Consistent with these findings, we demonstrate that increased AMPK phosphorylation is accompanied with increased \( Agrp \) expression (25 mM glucose) and decreased AMPK phosphorylation is associated with decreased \( Agrp \) abundance (5:5 mM glucose). The alteration of \( Agrp \) expression is mediated via AMPK because Cpd C prevents BHBA-induced aberrant \( Agrp \) expression under both glucose conditions. Hence, our results demonstrate the existence of the BHBA → AMPK → AGRP pathway.

The glucose/BHBA ratio and food intake

Whether this pathway is activated or inhibited seems to depend on glucose concentration. In this study using tumorous cells, we were able to demonstrate that in a medium containing 25 mM glucose, 6 mM BHBA elicits increased expression of \( Agrp \), whereas under culture conditions of 5:5 mM glucose, \( Agrp \) expression was significantly reduced. Thus, we investigated glucose/BHBA ratio of ~4:1 and ~1:1 respectively. The high glucose/BHBA ratio used in our study might be comparable with high plasma glucose concentrations (glucose/BHBA ratio of ~4:1) observed in patients with diabetic ketosis (Sheikh-Ali et al. 2008), a metabolic situation associated with hyperphagia (Toyonaga et al. 2002). Similarly, streptozotocin–treated rats are hyperglycaemic, ketoacidotic and hyperphagic (Goodman 1987, Friedman & Ramirez 1994), although this might also be due to insulin deficiency. Moreover, consumption of high-fat diets, which increase circulating glucose and BHBA concentrations, leads to increased meal size and greater energy intake in rodent and humans (Warwick 1996, Hu et al. 2004). Also, pregnant cows possessing higher plasma BHBA and glucose concentrations (glucose/BHBA ratio of ~3:1) due to feeding a ketogenic diet show the higher feed intake

---

Figure 5 BHBA increases AMPK-mediated orexigenic \( Agrp \) expression in hypothalamic GT1-7 cells cultured in 25 mM glucose-containing medium (A). In contrast, BHBA decreases \( Agrp \) expression in hypothalamic GT1-7 cells cultured in 5:5 mM glucose-containing medium (B). GT1-7 cells were either stimulated with BHBA (6 mM) alone or preincubated with 1 \( \mu \)M of the MCT1 inhibitor pHMB or with 10 \( \mu \)M of the AMPK inhibitor Cpd C, respectively, followed by BHBA (6 mM) application. At times as indicated, transcript levels of \( Agrp \) and \( Gapdh \) were quantified by real-time PCR. \( 2^{-}\Delta\Delta C_{\text{T}} \) method was used to analyse the relative gene expression. The graph represents means ± S.D. originating from three independent experiments (for each time \( n_{5.5} = 5–12 \) and \( n_{25} = 7–13 \)). Mean values with different lowercase letters differ with \( P<0.05 \) (Tukey’s test; ANOVA: \( P<0.05 \), \( f_{5.5} = 6–3 \), \( f_{25} = 6–3 \)).

After 4 h BHBA treatment is associated with significantly raised AMPK phosphorylation in a culture medium containing 25 mM glucose. This inverse phosphorylation is in accordance with earlier findings in skeletal muscle cells and in C2C12 myoblast cells, showing that AMPK negatively controls mTOR signalling (Bolster et al. 2002, Du et al. 2007). Why under culture conditions of 5:5 mM glucose changes in mTOR phosphorylation (despite of observed p-AMPK changes) were not as pronounced as in 25 mM glucose is currently unknown.
compared with cows with lower plasma BHBA and glucose concentrations (Duske et al. 2009). Whether the increased feed intake in the situation of high glucose is due to or despite high BHBA remains to be investigated. However, the putative orexigenic characteristics of BHBA in the presence of high glucose could be explained by the fact that BHBA acts similar to 2-deoxyglucose as a glucose anti-metabolite, thereby inhibits glucose uptake and ATP production and may stimulate feed intake even at satiation (Minami et al. 1995).

BHBA treatment in the lower (5-5 mM) glucose (glucose/BHBA ratio of ~1:1)-containing medium, on the other hand, reflects the metabolic situation present in normo- or hypoglycaemic animals receiving BHBA infusions. Thus, for example, i.c.v. application of BHBA suppresses food intake in the long term in Wistar King A (Sakata et al. 1982) and Osborne–Mendel rats (Arase et al. 1988). However, in the study of Davis et al. (1981), only a numeric reduction of food intake upon i.c.v. BHBA infusion could be observed when compared with saline-treated controls. Women eating a very low-carbohydrate diet reveal significantly increased BHBA and normal glucose levels whereby food intake spontaneously decreased (Brehm et al. 2003). Additionally, early lactating cows with reduced glucose but elevated BHBA levels (glucose/BHBA ratio of 1:1) ate less than non-ketotic cows with a 4:1 ratio (Hammon et al. 2009). Thus, the majority of these studies indicate that BHBA exerts an anorexigenic role in the brain (in normo- or hypoglycaemia), and our results obtained from the studies in 5-5 mM glucose (glucose/BHBA ratio of 1:1) demonstrates that this may be due to reduced AMPK phosphorylation and reduced Agrp expression. The anorexic BHBA trait might be caused by the observation that BHBA serves under normal or lowered glucose condition as metabolite for ATP production and thus trigger for diminished Agrp expression. This mechanism would explain earlier findings, showing that the metabolic conversion of BHBA by the brain occurs primarily under hypoglycaemic conditions (Ruderman et al. 1974, Lindsay & Setchell 1976).

However, although the cell culture model used requires glucose and BHBA concentrations above those existing in vivo, the glucose/BHBA ratio investigated herein is highly comparable with the in vivo situation. Considering this fact, we propose a cellular pathway, which integrates BHBA in the control of food intake. Nevertheless, further cell and in vivo studies are necessary to confirm our current results by which BHBA regulates Agrp expression in dependency of the glucose level.

Conclusions

To summarise, we investigated a cellular pathway triggered in response to BHBA and provide new knowledge about BHBA’s possible impact on food intake regulation. We have demonstrated that BHBA is capable of entering the cell not only via MCT1 but also via other routes with subsequent mobilisation of calcium. Furthermore, BHBA modulates AMPK-α phosphorylation. Associated with an increased AMPK phosphorylation, Agrp mRNA expression increases after 4 h of BHBA treatment in a 25 mM glucose-containing medium. However, although in vitro conditions for GT1-7 cells require higher glucose concentrations, it is uncertain whether 25 mM glucose reflects any physiological relevance for in vivo comparisons. In the presence of 5-5 mM glucose, however, BHBA mobilises intracellular Ca2+ to a much lower extent and reduces AMPK phosphorylation and Agrp expression after 4 h. The latter cellular signal transduction mechanism may contribute to the understanding of the feed intake depressive effect of BHBA observed after in vivo infusions.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Acknowledgements

The authors thank Claudia Arlt, Claudia Reiko (FBN) and Sebastian Bühler (University of Rostock) for their skillful assistance and excellent technical support.

References


www.endocrinology-journals.org